Detalhe da pesquisa
1.
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.
Cell
; 185(3): 563-575.e11, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35120664
2.
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.
Cell
; 170(5): 927-938.e20, 2017 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28841418
3.
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
N Engl J Med
; 388(23): 2159-2170, 2023 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36972022
4.
Pathogenic germline variants in patients with endometrial cancer of diverse ancestry.
Cancer
; 130(4): 576-587, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37886874
5.
Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes.
Gynecol Oncol
; 182: 32-38, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38246044
6.
A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).
Gynecol Oncol
; 182: 75-81, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38262242
7.
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
Gynecol Oncol
; 186: 61-68, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603953
8.
Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Gynecol Oncol
; 180: 35-43, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38041901
9.
Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake.
Gynecol Oncol
; 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38493020
10.
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies.
Cancer
; 129(13): 2004-2012, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36951509
11.
Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination.
Cancer Immunol Immunother
; 72(1): 183-191, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35779095
12.
Landscape of chromatin remodeling gene alterations in endometrial carcinoma.
Gynecol Oncol
; 172: 54-64, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36958196
13.
TERT promoter mutations and gene amplification in endometrial cancer.
Gynecol Oncol
; 179: 16-23, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37890416
14.
Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.
Gynecol Oncol
; 178: 27-35, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37748268
15.
Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.
Gynecol Oncol
; 174: 262-272, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37245486
16.
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
Gynecol Oncol
; 176: 16-24, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37418832
17.
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
Gynecol Oncol
; 170: 93-101, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36669327
18.
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.
Gynecol Oncol
; 169: 64-69, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36512912
19.
Germline drivers of gynecologic carcinosarcomas.
Gynecol Oncol
; 174: 34-41, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37149903
20.
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Gynecol Oncol
; 174: 213-223, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37229879